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PIEWPOINT AND COMMENTARY
T-Segment Elevation Myocardial
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riage of Patients to Heart Attack Centers
s it Time for a National Policy for the
reatment of ST-Segment Elevation Myocardial Infarction?
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Despite substantial progress in the diagnosis and treatment of acute ST-segment elevation
myocardial infarction (STEMI), implementation of this knowledge into routine clinical
practice has been variable. It has become increasing clear that primary percutaneous coronary
intervention (PCI) is the preferred method of reperfusion if it can be performed in a timely
manner. Recent European data suggest that transfer for direct PCI may also be preferable to
fibrinolytic therapy. We believe it is time to establish a national policy for treatment of
patients with STEMI to develop a coordinated system of care similar to that of the level 1
trauma system. (J Am Coll Cardiol 2006;47:1339–45) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.101Cardiology Foundation
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1Knowing is not enough, we must apply. Willing is not enough,
we must do.
—Goethe (1)
n the past 20 years, substantial progress has been made in
he diagnosis and treatment of acute ST-segment elevation
yocardial infarction (STEMI) (2). The results from ran-
omized clinical trials indicate that the 30-day mortality has
ecreased from 25% to 30% to 4% to 6%. Advances in
eperfusion therapy, in particular both primary and post-
ytic percutaneous coronary intervention (PCI), have con-
ributed to a decrease in mortality and reinfarction rates.
he integration of these data into routine clinical practice,
owever, has been variable (3). Both fibrinolytic therapy and
CI may result in successful reperfusion of the infarct-
elated artery and lead to a decrease in morbidity and
ortality. It has become increasingly clear, however, that
rimary PCI is a superior treatment strategy if it can be
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ccepted May 15, 2005.erformed in a timely manner by an experienced team
4–6). Data also indicate that outcomes of patients with
TEMI are superior when they are managed by a cardio-
ascular specialist and in high-volume cardiac centers (7–
1). In this regard, treatment of STEMI has many similar-
ties to trauma. Definitive treatment of trauma victims in
he U.S. has been concentrated in trauma centers with clear
riage and treatment guidelines, leading to improved out-
omes (12,13). With this in mind, is it time to establish
ational or state policies with a coordinated system for the
reatment of STEMI? Should we adopt a policy of primary
CI in centers with cardiac catheterization laboratories as
ell as in centers within easy transfer distance? What
riteria should these heart attack centers possess? Who
hould play a leadership role in developing the criteria?
HE IDEAL METHOD OF REPERFUSION
he advantage of fibrinolytic therapy is its widespread
vailability, ease of use, and rapid administration. The
isadvantages include failure to open the infarct-related
rtery in 20% of patients and to provide complete reperfu-
ion (Thrombolysis In Myocardial Infarction [TIMI] flow
rade 2) in an additional 30%. Re-occlusion of the infarct-
elated artery occurs in up to 20% of patients when not
ollowed by PCI, and the risk of intracranial hemorrhage is
% to 2%, and substantially higher in the elderly. A wealth
f data suggest that fibrinolytic therapy is underutilized in
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National Policy for the Treatment of STEMI? April 4, 2006:1339–45he U.S. and relative contraindications are present in up to
0% of patients, which may temper its use (14).
The advantages of primary PCI are the high rate of
eperfusion success, its limited contraindications, and the
arly risk stratification made possible by angiography. The
rimary PCI strategy also results in improved clinical
utcomes, including reduced rates of recurrent ischemia and
nfarction, stroke, length of stay, and mortality (Fig. 1) (15).
he disadvantages are the lack of ready availability and
esources. Of the hospitals in the U.S., 25% have facilities
o perform primary PCI, and even fewer have 24-h avail-
bility. The best outcomes are likely obtained in high-
olume centers with high-volume operators. Approximately
wo-thirds of STEMI patients in the U.S. present to
ospitals without catheterization laboratories, but the vast
ajority are within reasonable transfer times to a hospital
ith PCI available. In Minnesota, for example, 70% of
ospitals without cardiac catheterization laboratories are
ocated within a 90-min transfer time to a high-volume PCI
enter (16).
The European Society of Cardiology has recently indi-
ated primary PCI (class I-A) as the recommended treat-
ent for STEMI if performed by an experienced team 90
in after first medical contact (17). The current American
ollege of Cardiology/American Heart Association (ACC/
HA) guidelines on STEMI recommend primary PCI as
n alternative to fibrinolytic therapy if done in a timely
ashion (90 min) by experienced providers (18). For patients
n cardiogenic shock or with contraindications to fibrinolytic
gents, both guidelines recommend primary PCI as the
ptimal reperfusion strategy (class I-B).
Abbreviations and Acronyms
NRMI-2  Second National Registry of Myocardial
Infarction
PCI  percutaneous coronary intervention
STEMI  ST-segment elevation myocardial infarctionigure 1. Trials comparing direct percutaneous coronary intervention with th
ercutaneous coronary intervention. PTCA  percutaneous transluminal coronMPLEMENTATION OF CLINICAL TRIAL RESULTS
espite the large quantity of data in STEMI (120,000
atients enrolled in randomized clinical trials), the wide-
pread and consistent implementation of these randomized
linical trial results has been disappointing (19). A quote
rom The Institute of Medicine report Crossing the Quality
hasm summarizes the problem:
Research on the quality of care reveals a health system that
frequently falls short in its ability to translate knowledge
into practice . . . care must be delivered by systems that are
carefully and consciously designed to provide care that is
safe, effective, patient centered, timely, efficient, and equi-
table . . . such systems must facilitate the applications of
scientific knowledge to practice and provide clinicians with
the tools and supports necessary to deliver evidence based
care consistently and safely (20).
number of studies have documented the delay in the
doption of therapies (for example, beta-blocker and aspi-
in) clearly shown to improve the outcome in STEMI
21,22). Likewise, data from the Second National Registry
f Myocardial Infarction (NRMI-2) have shown that reper-
usion therapy continues to be underutilized in the U.S., in
articular in high-risk groups such as women and the elderly
14). There is substantial geographic variation in the treat-
ent of STEMI that occurs within the same state and
egion, and the treatment of this life-threatening condition
nstead seems to be relegated to local clinical practice (23).
n particular, it seems that treatment in rural settings is less
ikely to adhere to clinical guidelines than that in urban
ettings (16,24).
UTCOMES IN SPECIALTY CENTERS
ata are available indicating that the outcome of STEMI
atients is better when treated by cardiovascular specialists.
or example, in-hospital, 30-day, and 1-year morality were
ignificantly reduced in patients treated by cardiologists
hen compared with other physicians. Cardiologist-treated
atients had higher utilization of cardiac procedures and
edications associated with survival (7). Admission torombolytic therapy show a significant reduction in events with primary
ary angioplasty. Reprinted, with permission, from Keeley et al. (15).
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as also associated with lower 30-day mortality in elderly
atients with STEMI than admission to unranked hospitals
25). It has become increasingly clear as well that the results
f PCI (both primary and elective procedures) are better in
he hands of high-volume operators in high-volume centers.
or example, mortality was lower in patients treated with
rimary PCI versus fibrinolytic agents at hospitals with
ntermediate (4.5% vs. 5.9%, p  0.001) and high volumes
3.4% vs. 5.4%, p  0.001). In contrast, in low-volume
enters, mortality with primary PCI was similar to that with
brinolytic agents (6.2% vs. 5.9%) (8). A retrospective study
sing data from the Cooperative Cardiovascular Project
ound that patients admitted to low-volume hospitals had a
7% higher mortality rate at 30 days than patients admitted
irectly to hospitals with more experience treating STEMI
9). Delays in door-to-balloon times are also more common
n low-volume centers (49 primary PCIs per year) (26).
lthough these studies are not randomized or of the best
cientific methods, the results are overwhelmingly consis-
ent showing that high-volume systematic approaches with
hese procedures yield the best outcome results.
AFETY OF TRANSFER
nitial reports suggested excellent safety and potential ben-
fits of transferring patients with STEMI for primary or
escue PCI from hospitals without the availability of a
atheterization laboratory (27–29). Several recent random-
zed controlled trials further support the safety and effec-
iveness of transferring acute STEMI patients for primary
CI from community hospitals that do not have PCI
apabilities.
ECENT CLINICAL TRIALS REGARDING TRANSFER
he first of these was the PRimary Angioplasty in patients
ransferred from General community hospitals to special-
zed PTCA Units with or without Emergency thrombolysis
PRAGUE) study, a multicenter, randomized controlled
rial designed to find the best reperfusion strategy in 300
atients with STEMI presenting to community hospitals
ithout cardiac catheterization laboratories (30). The lowest
ate of death, myocardial infarction, or stroke at 30 days
ccurred in patients transferred for primary PCI (8%) versus
5% in patients receiving streptokinase during transfer for
acilitated PCI and 23% for patients treated with streptoki-
ase without transfer. There were no deaths during trans-
ers. The mean door-to-balloon (from the community
ospital) time was 95 min in the primary PCI group versus
08 min in the fibrinolysis and transfer group. The
RAGUE-2 study was a larger nationwide trial in the
zech Republic comparing intravenous streptokinase versus
ransfer for primary PCI in patients (n  850) with STEMI
resenting to hospitals without PCI capabilities. The pri-
ary end point, 30-day mortality (intention to treat), was0% in the streptokinase group compared with 6.8% in the oCI group (p  0.12), and death/reinfarction/stroke at 30
ays was 15.2% in the streptokinase group versus 8.4% in
he PCI group (p  0.003) (31). In particular, patients who
resented 3 h after the onset of chest pain had signifi-
antly decreased mortality if transferred for primary PCI
15.3% streptokinase vs. 6.0% PCI; p  0.02). There were
ve complications (1.2%) during transfer, including two
eaths. Ventricular fibrillation developed in three patients,
nd they were successfully resuscitated.
The Danish Multicenter Randomized Study on Fibrino-
ytic Therapy versus Acute Coronary Angioplasty in Acute
yocardial Infarction (DANAMI-2) was a Danish na-
ional, multicenter, randomized controlled trial comparing
rimary PCI with fibrinolysis for the treatment of STEMI
32). Participating in this trial were 24 referral hospitals
without angioplasty capability) and 5 invasive centers. The
istance from the referral hospitals to the invasive centers
anged from 35 to 95 miles. The results showed an overall
tatistically significant reduction of the primary end point of
eath, reinfarction, and stroke at 30 days for patients treated
ith primary PCI (8.0% for primary PCI vs. 13.7% for
brinolysis, p  0.001). Most of the difference was the rate
f reinfarction, which was much higher when patients
eceived only thrombolytic agents, and few underwent
ubsequent angiography. Of the 1,572 patients enrolled,
,129 (72%) presented initially to the referral hospitals and
ere randomized to fibrinolysis with front-loaded tissue
lasminogen activator versus transfer for primary PCI with-
ut the fibrinolytic agent. The results favoring primary PCI
ere also evident in patients who presented initially to the
eferral hospitals (8.5% for transfer for primary PCI vs.
4.2% for fibrinolysis, p  0.002). There were no deaths
uring transfer from the referral hospitals to the invasive
enters.
A small, predominately U.S. multicenter randomized
tudy, the Air Primary Angioplasty in Myocardial Infarction
Air-PAMI) study, also compared fibrinolysis with transfer
or primary PCI (33). The mean distance from the referral
ospitals to the PCI center was 32  36 miles. There were
o deaths or complications in any of the transferred pa-
ients. The mean door-to-balloon time in the group trans-
erred for primary PCI was 174  80 min, which is
onsiderably longer than in the European trials. Despite
hese delays, there was a trend toward fewer major adverse
ardiac events (death, reinfarction, or stoke) in the primary
CI group at 30 days (8.4% vs. 13.6%, p  0.33).
A recent meta-analysis involving six randomized trials
3,750 patients) compared the strategy of transfer for
rimary PCI versus on-site thrombolysis. Transfer time was
lways 3 h. The combined end point of death, reinfarc-
ion, or stroke was reduced by 42% favoring the transfer for
CI strategy (p  0.001) (Fig. 2) (34). In metropolitan
reas, the expanded use of pre-hospital electrocardio-
rams may allow direct transfer to designated PCI hospitals
nd further decrease door-to-balloon times and improve
utcomes (35,36).
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National Policy for the Treatment of STEMI? April 4, 2006:1339–45NFLUENCE OF TIME TO TREATMENT FOR PCI
lthough the correlation of time to treatment and outcome
ith fibrinolytic therapy is clear, there are less consistent
ata regarding the importance of time to treatment with
CI (37). The largest observational study from the
RMI-2 showed that the in-hospital mortality did not
ncrease significantly with increasing delay from symptom
nset to PCI. However, mortality did increase if door-to-
alloon times were 120 min (38). In an analysis from the
lobal Use of Strategies to Open Occluded Arteries in
cute Coronary Syndromes (GUSTO-IIb) study, 30-day
ortality rates of patients who underwent balloon inflation
60 min after study enrollment was 1%; 61 to 75 min,
.7%; 76 to 90 min, 4.0%; and 91 min, 6.4% (39). In an
nalysis of the Zwolle PCI trials, there was a strong
elationship between delay to PCI and outcomes in high-
isk patients, whereas time had little influence on those at
ow risk (40). In a recent review of 10 randomized trials of
CI versus fibrinolysis (2,635 patients), there was an in-
rease in major cardiac events associated with increased time
o presentation after fibrinolysis but not with PCI (41). In
his same review, the mortality benefit of PCI was especially
pparent in those who presented 4 h after onset of
ymptoms (fibrinolysis, 12.1% vs. PCI, 4.7%). Currently,
he bulk of data support that time delays, in particular 2 h
nd longer, affect outcomes in high-risk patients and that
atients who present after 4 h do better with primary PCI.
NALOGIES TO THE TRAUMA SYSTEM
o optimize treatment and meet the recommended door-
o-balloon times of 90 min or less, there needs to be an
fficient, coordinated system of regionalized cardiac care
imilar to the trauma system model. Such a system would
ncourage pre-arranged transfer agreements and protocols
etween the referring hospital and the PCI center.
The American College of Surgeons (ACS) has developed
igure 2. Meta-analysis of six randomized trials comparing transfer for
rimary percutaneous coronary intervention (PCI) versus on-site throm-
olysis shows a significant reduction in the combined end point of death,
einfarction, or stroke favoring transfer for PCI. Reprinted, with permis-
ion, from Dalby et al. (34).n organized system of regionalized trauma care to stan- Sardize and improve the care of critically injured trauma
atients (42). This system is organized on a state level with
versight and standards developed by the ACS. Hospitals
re accredited to level of service by the ACS. The level 1
enters are usually tertiary care centers with a commitment
o research. The level 2 trauma hospital may be a commu-
ity hospital that meets the standards of providing avail-
bility of appropriate physician specialties as well as diag-
ostic and other therapeutic resources. The level 3 facility
ay be a rural or suburban hospital where trauma patients
ill be initially stabilized and transferred to a level 1 or 2
rauma hospital using standardized transfer protocols and
uidelines. An important component of the trauma system
s the collection of outcome data in the form of a trauma
egistry (43). Such a system-wide approach has reduced
reventable trauma-related deaths (13,44,45). Seventy per-
ent of trauma deaths attributable to motor vehicle crashes
ccur in rural areas. One of the key components of the
rauma system is to train and assist rural practitioners in the
nitial treatment and stabilization of injured patients with
ppropriate triage guidelines that facilitate rapid transfer to
evel 1 and 2 trauma centers.
Because more than 70% of U.S. hospitals do not have
CI capability, an analogous, integrated, organized system
ould be developed for the treatment of STEMI. The
oncept of the “golden hour” in trauma care is analogous to
he “golden hour” and “time is muscle” concept of acute
ardiac care.
CCREDITATION AND QUALITY ASSURANCE
ables 1 and 2 outline the possible attributes of a STEMI
enter and consideration for transfer. Organizations such as
he ACC and the AHA could help in the development of
olicies and standards of excellence. Although national
tandards would be established, state or regional bodies
able 1. Criteria for Level 1 Heart Attack Center
24-h cardiac catheterization laboratory availability
24-h cardiovascular surgery availability
Comprehensive interventional cardiology and cardiovascular surgery
services
200 patients/yr (36 STEMI) per hospital
75 patients/yr per interventional cardiologist
Standardized protocols at referral and receiving hospitals
Transfer agreements in place
Education and training programs for transport, referral, and receiving
hospital personnel
Quality assurance program
TEMI  ST-segment elevation myocardial infarction.
able 2. Criteria for Transfer of STEMI Patients
Expected door-to-balloon time 90 min for patients 3 h after onset
of symptoms
Patients 3 h after onset of symptoms
Patients with cardiogenic shock or severe congestive heart failure
Patients with contraindications for thrombolytic therapyTEMI  ST-segment elevation myocardial infarction.
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April 4, 2006:1339–45 National Policy for the Treatment of STEMI?ould be responsible to ensure that they are implemented
n a local level. This system should be inclusive rather than
xclusive. All hospitals in a region would be encouraged to
articipate. Pre-hospital electrocardiograms obtained in the
mbulance now allow a strategy of triage and transporting
atients directly to hospitals with PCI capability. Unfortu-
ately, only 50% of myocardial infarction patients are trans-
orted to the hospital by ambulance (46). Therefore, hospitals
ithout PCI availability will also play a key role and will need
o be part of the system as well. The activities of the regional
ardiac system might include the following: 1) accreditation of
ospitals, 2) development of triage and transfer guidelines,
) facilitation of quality review, 4) promotion of educational
ctivities.
Although this system is particularly important for
TEMI, it may also be applied to other acute cardiovascular
vents such as stroke, aortic dissection, out-of-hospital
ardiac arrest, and high-risk non-STEMI patients, in whom
n early invasive approach seems warranted.
IGH-RISK PATIENTS
t the present time, a number of high-risk patient groups
lready require transfer to hospitals with PCI or cardiovas-
ular surgical capabilities. Patients in cardiogenic shock or
hose with contraindications to fibrinolytic agents would
ikely benefit from a more standardized approach than the
atient-specific emergency transfer that occurs now.
UTURE DIRECTIONS
here are a number of unresolved issues that will require
urther research to establish the optimal reperfusion strategy
or some patient subsets. Transfer for direct PCI seems to
e the best strategy for those patients who can be transferred
ithin 90 min to a PCI center. The ideal regimen of
djunctive therapy (glycoprotein IIb/IIIa inhibitors, clopi-
ogrel, reduced-dose fibrinolytic agents, and so on) needs to
e better defined before any can be recommended. The ideal
trategy for patients who present very early (1 h) or 120
in from a PCI center is still unclear. Fibrinolytic therapy
s very effective when used in the first hour of symptoms,
nd there may be no preferred approach when transfer times
re 2 h or longer. Certain subsets of patients, such as those
ho present 4 h from symptom onset, those in cardio-
enic shock, or elderly patients may benefit from transfer
egardless, and a standardized system may improve out-
omes. Another question to be addressed is whether pa-
ients treated with a fibrinolytic should be transferred for
ardiac catheterization immediately or only for clinical signs
f failed reperfusion for rescue PCI. The Southwest Ger-
any Interventional Study in Acute Myocardial Infarction
SIAM III) has recently shown a significant reduction in a
ombined end point of death, reinfarction, and target vessel
evascularization in STEMI patients receiving thrombolysis
ollowed by immediate stenting compared with a conserva-
ive approach with delayed stenting, but this observation beed confirmation in additional larger trials (47). There is
vidence from many trials showing that early PCI reduces
he rate of reinfarction and recurrent ischemia. Is there a
ole for pre-hospital fibrinolysis? Some of these questions
ay be answered as data become available from the large
acilitated PCI studies that are currently underway.
A coordinated system will allow implementation of treat-
ent guidelines specific for a state or region. In addition,
his system would be better equipped to implement new
dvances in diagnosis and treatment.
UMMARY
t the present time, the lack of a coordinated system of
TEMI care in the U.S. denies patients the benefits of
irect PCI, and too many eligible patients do not receive
eperfusion therapy at all. Approximately 500,000 patients
er year present with STEMI in U.S. hospitals (17). Based
n available data, a coordinated system for direct PCI would
revent 6 to 8 events per 100 patients, affecting 35,000
atients per year (15,35). Additionally, a coordinated system
ay significantly reduce the number of “eligible but un-
reated” patients. Finally, the potential long-term health
nd economic benefits of a coordinated system related to
reservation of left ventricular function with a subsequent
eduction in congestive heart failure, decreased need for
efibrillators, and so on, is difficult to quantify. In recent
ears there have been a number of investigators emphasizing
he importance of regionalization of care and centers of
xcellence for acute coronary syndromes, but we still do not
ave a coordinated approach to patients with STEMI
48–50).
Clearly there are a number of obstacles to the develop-
ent of a national STEMI policy that includes critical
conomic and political issues (51). The current reimburse-
ent policy would penalize community and rural hospitals
ithout cardiac catheterization laboratories when a patient
s transferred directly from the emergency department to a
CI center. An adjustment in this reimbursement strategy
ould need to be addressed on a national level. Theoret-
cally, establishing heart attack centers could make it less
ttractive for cardiologists to practice at the non-PCI
enters. We do not believe this would be the case, and in
act, closer coordination with centers of excellence would
nhance the overall cardiovascular care for community
nd rural hospitals as well as the centers of excellence.
he current 911 system for pre-hospital care is well
rganized. In contrast, there is considerable variation in
he inter-hospital transfer system. Current government
egulations (Emergency Medical Treatment And Labor
ct [EMTALA]) in fact may have the unintended
onsequence of delays in transfer. A key component of a
ational policy would be to coordinate the air and ground
ransport systems on a state-by-state level. Finally, cur-
ent resources even at tertiary cardiovascular centers may
e challenged in dealing with the volume of STEMI
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National Policy for the Treatment of STEMI? April 4, 2006:1339–45atients. Many tertiary centers intermittently experience
hortages of staff and bed capacity, and a national policy
f direct PCI would require a significant commitment on
he part of interventional cardiologists and technical staff
or PCI hospitals. We believe these obstacles are not
nsurmountable and that care for STEMI patients in the
.S. would improve. Once a standardized system was in
lace for STEMI, the system could be utilized to handle
ther cardiac emergencies as well, including high-risk
on-STEMI, aortic dissection, and out-of-hospital car-
iac arrest.
ONCLUSIONS
e have made a dramatic improvement in reducing mor-
ality in STEMI over the last three decades. Rapid reper-
usion of an infarct-related artery leads to a decrease in
orbidity and mortality. It is increasingly clear that primary
CI is the preferred approach, if performed in a timely
anner by an experienced operator. Implementation of
uidelines and improvements in clinical practice have been
ess than ideal. We believe it is time to establish a national
olicy with a coordinated system for the treatment of
TEMI.
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